Log In
BCIQ
Print this Print this
 

Fuzeon, enfuvirtide

Also known as: T-20

  Manage Alerts
Collapse Summary General Information
Company Alexion Pharmaceuticals Inc.
DescriptionViral fusion inhibitor peptide analog based on HIV gp41
Molecular Target HIV gp41
Mechanism of ActionViral fusion inhibitor
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection; Treat HIV infection in combination with other antiretroviral agents in treatment experienced patients; Treat HIV infection/AIDS; Treat HIV-1 infection in combination with other antiretrovirals; Treat multidrug-resistant HIV infection
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8,869.4M

$4,554.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/23/2015

$8,788.4M

$4,473.5M

0

10/05/2009

$81.0M

$81.0M

0

Get a free BioCentury trial today